Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Precision cancer therapy: profiting from tumor specific defects in the DNA damage tolerance system.

Buoninfante OA, Pilzecker B, Aslam MA, Zavrakidis I, van der Wiel R, van de Ven M, van den Berk PCM, Jacobs H.

Oncotarget. 2018 Apr 10;9(27):18832-18843. doi: 10.18632/oncotarget.24777. eCollection 2018 Apr 10.

2.

PrimPol prevents APOBEC/AID family mediated DNA mutagenesis.

Pilzecker B, Buoninfante OA, Pritchard C, Blomberg OS, Huijbers IJ, van den Berk PC, Jacobs H.

Nucleic Acids Res. 2016 Jun 2;44(10):4734-44. doi: 10.1093/nar/gkw123. Epub 2016 Feb 28.

3.

Quantitative analysis by next generation sequencing of hematopoietic stem and progenitor cells (LSK) and of splenic B cells transcriptomes from wild-type and Usp3-knockout mice.

Lancini C, Gargiulo G, van den Berk PC, Citterio E.

Data Brief. 2016 Jan 8;6:556-61. doi: 10.1016/j.dib.2015.12.049. eCollection 2016 Mar.

4.

Roles of PCNA ubiquitination and TLS polymerases κ and η in the bypass of methyl methanesulfonate-induced DNA damage.

Wit N, Buoninfante OA, van den Berk PC, Jansen JG, Hogenbirk MA, de Wind N, Jacobs H.

Nucleic Acids Res. 2015 Jan;43(1):282-94. doi: 10.1093/nar/gku1301. Epub 2014 Dec 10.

5.

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells.

Lancini C, van den Berk PC, Vissers JH, Gargiulo G, Song JY, Hulsman D, Serresi M, Tanger E, Blom M, Vens C, van Lohuizen M, Jacobs H, Citterio E.

J Exp Med. 2014 Aug 25;211(9):1759-77. doi: 10.1084/jem.20131436. Epub 2014 Aug 11.

6.

Differential programming of B cells in AID deficient mice.

Hogenbirk MA, Heideman MR, Velds A, van den Berk PC, Kerkhoven RM, van Steensel B, Jacobs H.

PLoS One. 2013 Jul 29;8(7):e69815. doi: 10.1371/journal.pone.0069815. Print 2013.

7.

Rev1 is essential in generating G to C transversions downstream of the Ung2 pathway but not the Msh2+Ung2 hybrid pathway.

Krijger PH, Tsaalbi-Shtylik A, Wit N, van den Berk PC, de Wind N, Jacobs H.

Eur J Immunol. 2013 Oct;43(10):2765-70. doi: 10.1002/eji.201243191. Epub 2013 Aug 5.

8.

PCNA ubiquitination-independent activation of polymerase η during somatic hypermutation and DNA damage tolerance.

Krijger PH, van den Berk PC, Wit N, Langerak P, Jansen JG, Reynaud CA, de Wind N, Jacobs H.

DNA Repair (Amst). 2011 Oct 10;10(10):1051-9. doi: 10.1016/j.dnarep.2011.08.005. Epub 2011 Sep 1.

PMID:
21889916
9.

Lysine residue 185 of Rad1 is a topological but not a functional counterpart of lysine residue 164 of PCNA.

Wit N, Krijger PH, van den Berk PC, Jacobs H.

PLoS One. 2011 Jan 31;6(1):e16669. doi: 10.1371/journal.pone.0016669.

10.

HLTF and SHPRH are not essential for PCNA polyubiquitination, survival and somatic hypermutation: existence of an alternative E3 ligase.

Krijger PH, Lee KY, Wit N, van den Berk PC, Wu X, Roest HP, Maas A, Ding H, Hoeijmakers JH, Myung K, Jacobs H.

DNA Repair (Amst). 2011 Apr 3;10(4):438-44. doi: 10.1016/j.dnarep.2010.12.008. Epub 2011 Jan 26.

11.

The Fanconi anemia core complex is dispensable during somatic hypermutation and class switch recombination.

Krijger PH, Wit N, van den Berk PC, Jacobs H.

PLoS One. 2010 Dec 29;5(12):e15236. doi: 10.1371/journal.pone.0015236.

12.

Dependence of nucleotide substitutions on Ung2, Msh2, and PCNA-Ub during somatic hypermutation.

Krijger PH, Langerak P, van den Berk PC, Jacobs H.

J Exp Med. 2009 Nov 23;206(12):2603-11. doi: 10.1084/jem.20091707. Epub 2009 Nov 9.

13.

Somatic hypermutation of immunoglobulin genes: lessons from proliferating cell nuclear antigenK164R mutant mice.

Langerak P, Krijger PH, Heideman MR, van den Berk PC, Jacobs H.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):621-9. doi: 10.1098/rstb.2008.0223.

14.

A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification.

Langerak P, Nygren AO, Krijger PH, van den Berk PC, Jacobs H.

J Exp Med. 2007 Aug 6;204(8):1989-98. Epub 2007 Jul 30.

15.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
16.

HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.

Weimar IS, Weijer K, van den Berk PC, Muller EJ, Miranda N, Bakker AQ, Heemskerk MH, Hekman A, de Gast GC, Gerritsen WR.

Br J Cancer. 1999 Sep;81(1):43-53.

17.

Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells.

Weimar IS, Voermans C, Bourhis JH, Miranda N, van den Berk PC, Nakamura T, de Gast GC, Gerritsen WR.

Leukemia. 1998 Aug;12(8):1195-203.

18.

Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide.

Hooijberg E, Visseren MJ, van den Berk PC, Jellema AP, Romeijn P, Sein JJ, van der Voort EI, Hekman A, Ossendorp F, Melief CJ.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):346-56.

PMID:
8941874
19.

Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody.

Hooijberg E, Sein JJ, van den Berk PC, Hekman A.

Hybridoma. 1996 Feb;15(1):23-31.

PMID:
9064283
20.

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.

Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.

Cancer Res. 1995 Jun 15;55(12):2627-34.

21.

Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.

Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.

Cancer Res. 1995 Feb 15;55(4):840-6.

Supplemental Content

Loading ...
Support Center